Key features and details
- Horse polyclonal to Hepatitis B Virus Surface Antigen (Ad/Ay)
- Suitable for: ELISA
- Reacts with: Hepatitis B virus
- Isotype: IgG
Product nameAnti-Hepatitis B Virus Surface Antigen (Ad/Ay) antibody
See all Hepatitis B Virus Surface Antigen (Ad/Ay) primary antibodies
DescriptionHorse polyclonal to Hepatitis B Virus Surface Antigen (Ad/Ay)
SpecificityThis antibody is specific for Hepatitis B surface antigen
Tested applicationsSuitable for: ELISAmore details
Species reactivityReacts with: Hepatitis B virus
Immunization of horses with highly purified Ad/Ay antigen.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Constituents: 0.0268% PBS, 0.87% Sodium chloride
Concentration information loading...
Purification notesThis antibody was immunoaffinity purified from non-recombinant hepatitis antigens.
Our Abpromise guarantee covers the use of ab9193 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
RelevanceHepatitis B Virus (HBV) infection induces a disease state characterised by liver damage, inflammation and viral persistence. Infection also increases the risk of hepatocellular carcinoma. HBV belongs to the Hepadnaviridae family of viruses. Its genome consists of partially double stranded circular DNA. The DNA is enclosed in a nucleocapsid, or core antigen (HBcAg), which is surrounded by a spherical envelope (surface antigen or HBsAg). The core antigen shares its sequences with the e antigen (HBeAg) but no cross reactivity between the two proteins has been observed. The HBV genome also encodes a DNA polymerase that also acts as a reverse transcriptase. Hepatitis B infection is normally diagnosed from serological tests that detect HBsAg but as the disease progresses this antigen may no longer be present in the blood and tests for HBcAg are used. If HBsAg can be detected in the blood for longer than six months, chronic hepatitis B is diagnosed. The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr.
Cellular localizationVirion membrane
- Entrez Gene: 2828293 Hepatitis B virus
- Entrez Gene: 944569 Hepatitis B virus
- SwissProt: P03138 Hepatitis B virus
- SwissProt: P03140 Hepatitis B virus
- SwissProt: P03141 Hepatitis B virus
- SwissProt: Q81157 Hepatitis B virus
- SwissProt: Q81158 Hepatitis B virus
- SwissProt: Q81159 Hepatitis B virus
- HBsAg antibody
- HBV major surface antigen antibody
- HBV surface antigen antibody
ab9193 has been referenced in 14 publications.
- Huang LH et al. Development of a Transgenic Flammulina velutipes Oral Vaccine for Hepatitis B. Food Technol Biotechnol 57:105-112 (2019). PubMed: 31316282
- Gani AW et al. An Automated, Quantitative, and Multiplexed Assay Suitable for Point-of-Care Hepatitis B Virus Diagnostics. Sci Rep 9:15615 (2019). PubMed: 31666635
- Passioura T et al. De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. Cell Chem Biol 25:906-915.e5 (2018). PubMed: 29779957
- Song J et al. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem N/A:N/A (2018). PubMed: 29904948
- Kim DH et al. Intracellular interleukin-32? mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun 9:3284 (2018). PubMed: 30115930